Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.

Issue 3, 2012
Previous Article Next Article

Didemnins, tamandarins and related natural products

Author affiliations


Covering: 2002 to 2011

Since the discovery and isolation of the didemnin family of marine depsipeptides in 1981, the synthesis and biological activity of its congeners have been of great interest to the scientific community. The didemnins have demonstrated antitumor, antiviral, and immunosuppressive activity at low nano- and femtomolar levels. Of the congeners, didemnin B was the first marine natural product to reach phase II clinical trials in the United States, stimulating many analogue syntheses to date. About two decades later, tamandarins A and B were isolated, and were found to possess very similar structure and biological activity to that of the didemnin B. These compounds have shown impressive biological activity and some progress has been made in establishing structure–activity relationships. However, their molecular mechanism of action still remains unclear. This review highlights the long-standing study of didemnins and its critical application towards the understanding of the molecular mechanism of action of tamandarins and their potential use as therapeutic agents.

Graphical abstract: Didemnins, tamandarins and related natural products

Back to tab navigation

Article information

26 Aug 2011
First published
23 Jan 2012

Nat. Prod. Rep., 2012,29, 404-424
Article type
Review Article

Didemnins, tamandarins and related natural products

J. Lee, J. N. Currano, P. J. Carroll and M. M. Joullié, Nat. Prod. Rep., 2012, 29, 404
DOI: 10.1039/C2NP00065B

Social activity

Search articles by author